Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M248,017Revenue $M53,634Net Margin (%)38.3Altman Z-Score3.4
Enterprise Value $M264,765EPS $4.1Operating Margin %19.6Piotroski F-Score5
P/E(ttm)12.8Beneish M-Score-2.3Pre-tax Margin (%)21.5Higher ROA y-yY
Price/Book3.310-y EBITDA Growth Rate %1.4Quick Ratio0.6Cash flow > EarningsN
Price/Sales4.95-y EBITDA Growth Rate %-2.1Current Ratio0.8Lower Leverage y-yY
Price/Free Cash Flow24.6y-y EBITDA Growth Rate %12.4ROA % (ttm)15.5Higher Current Ratio y-yN
Dividend Yield %2.6PEG--ROE % (ttm)27.3Less Shares Outstanding y-yY
Payout Ratio %66.0Shares Outstanding M2,420ROIC % (ttm)10.4Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSKahn Brothers 2015-06-30 Reduce-0.05%$98.34 - $105.5
($102.32)
$ 102.690%Reduce 9.12%28,143
NVSKen Fisher 2015-06-30 Add0.01%$98.34 - $105.5
($102.32)
$ 102.690%Add 1.08%6,054,640
NVSDodge & Cox 2015-03-31 Reduce-0.02%$91.67 - $103
($98.99)
$ 102.694%Reduce 0.58%50,032,795
NVSTweedy Browne 2015-03-31 Reduce-0.01%$91.67 - $103
($98.99)
$ 102.694%Reduce 2.19%260,217
NVSHOTCHKIS & WILEY 2015-03-31 Sold Out -0.0031%$91.67 - $103
($98.99)
$ 102.694%Sold Out0
NVSMario Gabelli 2015-03-31 Add$91.67 - $103
($98.99)
$ 102.694%Add 2.61%9,840
NVSKen Fisher 2015-03-31 Reduce$91.67 - $103
($98.99)
$ 102.694%Reduce 0.29%5,990,224
NVSRuane Cunniff 2014-12-31 Sold Out $85.02 - $96.65
($92.56)
$ 102.6911%Sold Out0
NVSHOTCHKIS & WILEY 2014-09-30 Reduce-0.21%$85.25 - $94.8
($90.27)
$ 102.6914%Reduce 98.51%9,646
NVSRuane Cunniff 2014-09-30 Buy $85.25 - $94.8
($90.27)
$ 102.6914%New holding7,772
NVSHOTCHKIS & WILEY 2014-06-30 Reduce-0.52%$82.51 - $90.98
($87.73)
$ 102.6917%Reduce 71.80%649,519
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 102.6917%Add 10.04%51,102,219
NVSChris Davis 2013-09-30 Sold Out -0.01%$70.66 - $77.08
($73.84)
$ 102.6939%Sold Out0
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 102.6941%Sold Out0
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 102.6951%Reduce 85.39%726,200
NVSKahn Brothers 2013-03-31 Reduce-0.1%$63.3 - $71.32
($67.87)
$ 102.6951%Reduce 21.03%33,456
NVSVanguard Health Care Fund 2012-12-31 Reduce-0.99%$58.97 - $63.96
($61.82)
$ 102.6966%Reduce 70.59%1,461,400
NVSDodge & Cox 2012-12-31 Add0.11%$58.97 - $63.96
($61.79)
$ 102.6966%Add 2.65%48,438,459
NVSKahn Brothers 2012-12-31 Add0.04%$58.97 - $63.96
($61.82)
$ 102.6966%Add 10.43%42,368
NVSHOTCHKIS & WILEY 2012-12-31 Reduce-0.02%$58.97 - $63.96
($61.82)
$ 102.6966%Reduce 1.98%2,313,613
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15584.6view

Quarterly/Annual Reports about NVS:

    News about NVS:

    Articles On GuruFocus.com
    Bill Frels' Stocks With Highest-Growing Yields Jun 26 2015 
    Bill Frels' Stocks With Growing Yields Jun 27 2015 
    Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
    Follow Bill Ackman in Valeant Pharmaceuticals Jun 19 2015 
    Billionaire George Soros Ups Two Stakes in First Quarter Jun 16 2015 
    Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
    Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
    8 Top Healthcare Stocks to Watch May 13 2015 
    Amgen Reports An Upbeat Q1 Earnings Apr 23 2015 
    Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 

    More From Other Websites
    Why Novartis’s Revenues Declined Marginally Jul 28 2015
    Novartis’s Adjusted Earnings per Share Declined 7% in 2Q15 Jul 28 2015
    New heart drugs come in more expensive than expected Jul 27 2015
    7:12 am Novartis AG's Revolade recommended by CHMP for EU approval to treat patients with severe... Jul 26 2015
    FDA OK's Odomzo from Novartis for common skin cancer type Jul 24 2015
    FDA OK's Odomzo from Novartis for common skin cancer type Jul 24 2015
    FDA OK's Odomza from Novartis for common skin cancer type Jul 24 2015
    AbbVie: Beware the Biosimilars? Jul 24 2015
    Court of Appeals Biosimilars Decision Does Not Assure Zarxio Launch in September Jul 22 2015
    Novartis (NVS) Beats on Earnings in Q2, 2015 View Retained - Analyst Blog Jul 22 2015
    Company News for July 22, 2015 - Corporate Summary Jul 22 2015
    Novartis Can Sell Copycat of Amgen’s Neupogen in September, Court Rules Jul 21 2015
    Appeals court says rival can sell copy of Amgen drug Neupogen Jul 21 2015
    Court ruling clears way for Novartis' low-cost biotech drug Jul 21 2015
    Court ruling clears way for Novartis' low-cost biotech drug Jul 21 2015
    Novartis (NVS) Earnings Report: Q2 2015 Conference Call Transcript Jul 21 2015
    Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles Jul 21 2015
    European stocks end winning streak Jul 21 2015
    European stocks end winning streak Jul 21 2015
    European shares fall, pulled down by drugmakers Jul 21 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK